Literature DB >> 3160355

Impaired killer cell generation in the autologous mixed leukocyte reaction by rheumatoid arthritis lymphocytes.

M Goto, N J Zvaifler.   

Abstract

Natural killer-like cells are generated along with interleukin-2 (IL-2) in the autologous mixed leukocyte reaction (AMLR). Patients with active rheumatoid arthritis (RA), but not those whose disease is in remission, are poor producers of AMLR killer cells. This defect cannot be explained by age, medications, or serum factors. The impaired generation of natural killer-like cells was not influenced by gamma-interferon but could be partially restored by addition of indomethacin to the AMLR culture, or by culturing RA T cells with exogenous IL-2. However, the response of RA T cells to IL-2 was significantly less than that of controls. These results suggest that the defect in the generation of AMLR killer cells in patients with active RA may be due in part to defective production of IL-2 and a lesser sensitivity of RA T cells to IL-2.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3160355     DOI: 10.1002/art.1780280703

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  3 in total

1.  Modulation of human T cell functions by surface sulphydryl groups: differential effects on IL-2 production and responsiveness.

Authors:  S Smith; C H Brown-Galatola; N D Hall
Journal:  Clin Exp Immunol       Date:  1992-04       Impact factor: 4.330

2.  A sensitive radioimmunoassay for alpha-interferon: circulating alpha-interferon-like substance in the plasma of healthy individuals and rheumatoid arthritis patients.

Authors:  S Shiozawa; K Chihara; K Shiozawa; T Fujita; H Ikegami; S Koyama; M Kurimoto
Journal:  Clin Exp Immunol       Date:  1986-10       Impact factor: 4.330

3.  Lymphokine-activated killer cell activity in rheumatoid arthritis.

Authors:  M Jíra; M Malkovský; A M Denman; B Loveland; D Lyons; A G Dalgleish; A D Webster
Journal:  Clin Exp Immunol       Date:  1987-06       Impact factor: 4.330

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.